Geron

GERN

Market cap $836M

2026 RYTELO ® (imetelstat) net product revenue expected in the range of $220 to $240 million 2026 total operating expenses expected in the range of $230 to $240 million Expected top-line growth and streamlined operations to support path toward building a sustainable hematology company FOSTER CITY, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, aiming to change lives by changing the course of blood cancer, today announced 2026 financial guidance.

FOSTER CITY, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective December 17, 2025, it granted stock options to purchase an aggregate of 320,000 shares of common stock to one newly hired employee as an inducement material to such employee's acceptance of employment with Geron.

Restructuring Supports RYTELO® U.S. Commercial Strategy and Investment in Clinical Development Expected to Reduce 2026 Projected Operating Expenses FOSTER CITY, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced a strategic restructuring plan intended to position the Company for long-term value creation for patients and shareholders and improve its financial discipline.

Oral presentation from pooled analyses of the IMerge population suggests that treatment-emergent cytopenias may reflect on-target effects associated with meaningful clinical outcomes, including hemoglobin increases and transfusion independence in lower-risk MDS

Geron reported Q3'25 Rytelo revenues of $47.2M, down from $49M in Q2, with no underlying increase in demand reported. Despite efforts to boost Rytelo's use in first and second-line therapy (now 36%, up from 30%), revenue growth remains elusive for GERN. Recent leadership changes include the departure of COO Andrew Grethlein and CCO Jim Ziegler, with Ahmed ElNawawi stepping in as CCO.

Geron Corporation ( GERN ) Q3 2025 Earnings Call November 5, 2025 8:00 AM EST Company Participants Dawn Schottlandt - Senior Vice President of Investor Relations & Corporate Affairs Harout Semerjian - CEO, President & Director Joseph Eid - Executive VP of Research & Development and Chief Medical Officer Michelle Robertson - Executive VP, CFO, Treasurer and Principal Financial & Accounting Officer Ahmed ElNawawi Conference Call Participants Tara Bancroft - TD Cowen, Research Division Stephen Willey - Stifel, Nicolaus & Company, Incorporated, Research Division Emily Bodnar - H.C. Wainwright & Co, LLC, Research Division Faisal Khurshid - Leerink Partners LLC, Research Division Presentation Operator Hello, and welcome to the Geron Corporation Third Quarter 2025 Earnings Call.

Geron (GERN) came out with a quarterly loss of $0.03 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.04 per share a year ago.

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today reported financial results for the third quarter of 2025 and recent business highlights. "The high unmet need in lower-risk MDS is well known, and RYTELO is a therapy with a novel mechanism of action and the potential to significantly impact the treatment paradigm. There is work ahead of us to fully maximize the.

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that Harout Semerjian, Chief Executive Officer, is scheduled to present at the following investor conferences: Stifel 2025 Healthcare Conference Fireside chat on Tuesday, November 11 at 11:40 AM ET in New York, NY 8th Annual Evercore Healthcare Conference Fireside chat on Tuesday, December 2 at 11:15 A.

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that five abstracts – one oral and four poster presentations – have been accepted for presentation at the 67th American Society of Hematology (ASH) 2025 Annual Meeting, to be held December 6-9, 2025 in Orlando, FL. The data feature new clinical and translational analyses of RYTELO (imetelstat) across l.